Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sponsors Will Need New Databases And Metrics To Determine Success Of Opioids REMS

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA sees REMS assessment as a collaborative effort and already has initiatives with other federal agencies to find ways to monitor indicators of effectiveness.

You may also be interested in...



FDA Wants Fast Turnaround In Assessing Opioid REMS' Effectiveness

The agency tells companies to submit proposals in 120 days, and expects to have the REMS in place by the beginning of 2012. The first assessment would be due at six months.

FDA Wants Fast Turnaround In Assessing Opioid REMS' Effectiveness

The agency tells companies to submit proposals in 120 days, and expects to have the REMS in place by the beginning of 2012. The first assessment would be due at six months.

Opioid REMS Could Be Linked To CME, FDA Suggests

Advisory committee panel members will weigh in on the value of common educational materials and the metrics for success.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070832

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel